Bronchopulmonary PK of AT-527 (R07496998)

A

Atea Pharmaceuticals

Status and phase

Completed
Phase 1

Conditions

Healthy Volunteer Study

Treatments

Drug: AT-527

Study type

Interventional

Funder types

Industry

Identifiers

NCT04877769
AT-03A-007

Details and patient eligibility

About

This study will assess the safety, tolerability and bronchopulmonary pharmacokinetics (PK) of AT-527 (R07496998)

Enrollment

24 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Subjects must agree to use birth control, as required by the protocol.
  • Females must have a negative pregnancy test at Screening and prior to dosing
  • Minimum body weight of 50 kg and body mass index (BMI) of 18-29 kg/m2
  • Willing to comply with the study requirements and to provide written informed consent

Exclusion criteria

  • Infected with hepatitis B virus, hepatitis C virus, HIV or SARS-CoV-2
  • Abuse of alcohol or drugs
  • Use of other investigational drugs within 28 days of dosing
  • Concomitant use of prescription medications, or systemic over-the-counter medications
  • Other clinically significant medical conditions or laboratory abnormalities

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Sequential Assignment

Masking

None (Open label)

24 participants in 3 patient groups

AT-527 Group A
Experimental group
Description:
n=8
Treatment:
Drug: AT-527
AT-527 Group B
Experimental group
Description:
n=8
Treatment:
Drug: AT-527
AT-527 Group C
Experimental group
Description:
n=8
Treatment:
Drug: AT-527

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems